The contract development and manufacturing organization (CDMO) currently employs 37 staff in the US across several locations in Newark, DE, where the new large-scale pharmaceutical production facility will be located. It also has operations in Suzhou Jiangsu, China.
"This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US," said Hui-Yin Harry Li, PhD, president and CEO of Wilmington PharmaTech in a press release.
"This expansion scales up operations and significantly enhances offerings to our clients in API manufacturing and related services. It also expands our portfolio of research, development, and potential commercial API services.”
Dr. Ke Li, PMP, PharmaTech's director of operations, yesterday presented the company's plans to the Council on Development Finance, requesting a $300,400 performance-based grant to support adding new jobs and a grant of $360,000 for assistance with capital costs.
PharmaTech has not responded to a request for comment.
